[go: up one dir, main page]

AR029155A1 - Combinacion y uso de la misma en la fabricacion de un medicamento util para tratar afecciones cardiovasculares - Google Patents

Combinacion y uso de la misma en la fabricacion de un medicamento util para tratar afecciones cardiovasculares

Info

Publication number
AR029155A1
AR029155A1 ARP000100977A ARP000100977A AR029155A1 AR 029155 A1 AR029155 A1 AR 029155A1 AR P000100977 A ARP000100977 A AR P000100977A AR P000100977 A ARP000100977 A AR P000100977A AR 029155 A1 AR029155 A1 AR 029155A1
Authority
AR
Argentina
Prior art keywords
manufacture
combination
same
medicinal product
treat cardiovascular
Prior art date
Application number
ARP000100977A
Other languages
English (en)
Inventor
John C Alexander
Barbara Roniker
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR029155A1 publication Critical patent/AR029155A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Combinaciones de un inhibidor de ACE y un antagonista epoxi-esteroideo del receptor de aldosterona para su uso en el tratamiento de afecciones circulatorias. Resultan de particular interés las terapias que usan compuestos antagonistas tipo epoxi-esteroides del receptor de aldosterona, tales como eplerenona, en combinacion con un inhibidor de la enzima convertidora de angiotensina. Estas combinaciones de usan en la fabricacion de medicamentos utiles para tratar la insuficiencia cardíaca congestiva, al tiempo que se evitan o se reducen los efectos secundarios inducidos por el antagonista de aldosterona, tales como la hipercalemia.
ARP000100977A 1999-03-05 2000-03-03 Combinacion y uso de la misma en la fabricacion de un medicamento util para tratar afecciones cardiovasculares AR029155A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12297799P 1999-03-05 1999-03-05

Publications (1)

Publication Number Publication Date
AR029155A1 true AR029155A1 (es) 2003-06-18

Family

ID=22406014

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100977A AR029155A1 (es) 1999-03-05 2000-03-03 Combinacion y uso de la misma en la fabricacion de un medicamento util para tratar afecciones cardiovasculares

Country Status (24)

Country Link
US (1) US20040077611A1 (es)
EP (2) EP1165136B1 (es)
JP (1) JP2002538172A (es)
KR (1) KR100580286B1 (es)
CN (1) CN1229141C (es)
AR (1) AR029155A1 (es)
AT (2) ATE249242T1 (es)
AU (2) AU778559B2 (es)
BR (1) BR0008781A (es)
CA (1) CA2364169A1 (es)
DE (2) DE60024335T2 (es)
DK (2) DK1382351T3 (es)
EA (1) EA004064B1 (es)
ES (2) ES2206204T3 (es)
HK (1) HK1042252B (es)
HU (1) HUP0200519A2 (es)
IL (2) IL145237A0 (es)
MX (1) MXPA01009035A (es)
NZ (1) NZ514205A (es)
PT (1) PT1165136E (es)
SI (1) SI1165136T1 (es)
TR (1) TR200102581T2 (es)
WO (1) WO2000051642A1 (es)
ZA (1) ZA200107779B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008056A (es) * 1999-12-08 2003-07-21 Pharmacia Corp Forma cristalina de eplerenona que exhibe velocidad de disolucion intensificada.
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
EP1580193A3 (en) * 1999-12-08 2010-06-23 Pharmacia Corporation Eplerenone crystalline form
CN100413881C (zh) * 1999-12-08 2008-08-27 法马西亚公司 依匹乐酮晶形
US20010039262A1 (en) * 2000-04-26 2001-11-08 Balaji Venkataraman Methods and compositions for the treatment of cardiac indications
CA2419256A1 (en) * 2000-08-28 2002-03-07 Kenton N. Fedde Use of an aldosterone receptor antagonist to improve cognitive function
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
WO2014018930A1 (en) * 2012-07-27 2014-01-30 Isis Pharmaceuticals. Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
CN106267147A (zh) * 2015-06-10 2017-01-04 上药东英（江苏）药业有限公司 一种复方降压药物组合物
MY200263A (en) 2015-10-08 2023-12-18 Ionis Pharmaceuticals Inc Compounds and methods for modulating angiotensinogen expression
LT4136092T (lt) 2020-11-18 2024-09-25 Ionis Pharmaceuticals, Inc. Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
CN1142793C (zh) * 1995-06-07 2004-03-24 G·D·瑟尔公司 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Also Published As

Publication number Publication date
PT1165136E (pt) 2004-02-27
ATE249242T1 (de) 2003-09-15
HK1042252B (en) 2004-04-23
EA200100951A1 (ru) 2002-04-25
DE60024335D1 (de) 2005-12-29
DE60024335T2 (de) 2006-08-03
EP1165136B1 (en) 2003-09-10
HK1061200A1 (en) 2004-09-10
HK1042252A1 (en) 2002-08-09
SI1165136T1 (en) 2004-02-29
ES2206204T3 (es) 2004-05-16
WO2000051642A1 (en) 2000-09-08
CN1229141C (zh) 2005-11-30
EP1382351A1 (en) 2004-01-21
AU778559B2 (en) 2004-12-09
DK1165136T3 (da) 2004-01-12
AU3394500A (en) 2000-09-21
NZ514205A (en) 2004-07-30
IL145237A0 (en) 2002-06-30
HUP0200519A2 (hu) 2002-07-29
CA2364169A1 (en) 2000-09-08
ZA200107779B (en) 2002-12-20
EP1165136A1 (en) 2002-01-02
JP2002538172A (ja) 2002-11-12
EP1382351B1 (en) 2005-11-23
EA004064B1 (ru) 2003-12-25
CN1372475A (zh) 2002-10-02
DE60005159T2 (de) 2004-07-22
KR20010108319A (ko) 2001-12-07
DK1382351T3 (da) 2006-01-23
MXPA01009035A (es) 2004-08-12
TR200102581T2 (tr) 2002-04-22
IL145237A (en) 2006-08-01
ES2250803T3 (es) 2006-04-16
US20040077611A1 (en) 2004-04-22
ATE310537T1 (de) 2005-12-15
EP1382351B8 (en) 2006-03-08
AU2005201045A1 (en) 2005-04-07
DE60005159D1 (de) 2003-10-16
KR100580286B1 (ko) 2006-05-16
BR0008781A (pt) 2002-07-02

Similar Documents

Publication Publication Date Title
AR029155A1 (es) Combinacion y uso de la misma en la fabricacion de un medicamento util para tratar afecciones cardiovasculares
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
ECSP077309A (es) Compuestos amido y sus usos como farmaceuticos
CL2007002635A1 (es) Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
BR112012010010A2 (pt) piridinas bicíclicas e análogos como moduladores da sirtuína
CL2012000738A1 (es) Compuestos heterociclicos derivados de indol, inhibidores de xantina-oxidasa; composición farmacéutica que los comprende; procedimiento de preparación; y uso en el tratamiento de enfermedades tales como hiperuricemia, gota, insuficiencia cardiaca, hipertensión, diabetes, hiperlipidemia, obesidad, aterosclerosis, entre otras.
CL2011000306A1 (es) Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion.
SG155188A1 (en) Pyrrole derivatives as pharmaceutical agents
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
SV2011003901A (es) Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
EP2350129A4 (en) PD1 Antagonist Compositions and Methods for their Use
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
NO20084374L (no) Imidazoltiazolforbindelser for behandling av sykdom
CL2007002492A1 (es) Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras.
CL2008003188A1 (es) Compuestos derivados de piridina y pirazina; composicion farmaceutica que los comprende;y su uso en el tratamiento o prevencion de tumores sensibles a la inhibicion de enzimas del receptor ax1 y/o c-met.
BR112012013195A2 (pt) compostos de 2-piridona.
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
MX375222B (es) Compuestos y su uso para reducir los niveles de ácido úrico

Legal Events

Date Code Title Description
FB Suspension of granting procedure